These investigators are continually pursuing their long-term screening of medicinal plant extracts and subsequent structural modification of discovered leads. The goal of the proposed research is to discover novel anti-HIV compounds from plant-derived natural products and their analogs. Specifically, they plan to isolate and identify the potent anti-HIV principles from extracts of 71 previously unexplored plant species using bioassay-directed isolation and structural chacterization. Initially, inhibition of HIV replication is measured using an in vitro P24 antigen capture assay in H9 lymphocytes. The structures of isolated anti-HIV principles will be determined using modern spectral and x-ray analyses. Promising, new active leads will be selected for structural modification and synthesis of analogs on new active leads in order to determine structure-activity relationships as well as to improve their pharmacological profiles. Mechanisms of action will be investigated using biochemical and cell culture-based assays. These leads should provide new, effective, and less toxic drug candidates, which may circumvent drug resistance, target different stages in the viral life cycle, exhibit minimal toxicity, and have lower manufacturing costs. Two compounds, 4-methy DCK and DSB, have attractive properties for further development, based on novel mechanisms of action compared to approved HIV drugs; high in vitro potency against primary HIV-1 isolates; high in vitro therapeutic indices; and ease of synthesis. Studies of the compound's in vivo properties (pK, bioavailability and toxicity) are continuing, as are mechanism of action studies. Additional studies planned include in vitro analyses of the drug candidates' synergy or antagonism when used in combination with approved HIV drugs. In vitro studies of the rate of HIV resistance development will also be performed. The applicant hopes that at least one of these two structurally diverse compounds, or one of their analogs, should exhibit suitable properties for moving forward into preclinical toxicology testing and scale-up manufacturing during 2000, with the goal of submitting an IND by 2001.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI033066-12
Application #
6631939
Study Section
Special Emphasis Panel (ZRG1-AARR-3 (01))
Program Officer
Litterst, Charles L
Project Start
1992-08-01
Project End
2004-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
12
Fiscal Year
2003
Total Cost
$388,835
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Liu, Qingbo; Li, Wei; Huang, Li et al. (2018) Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. Eur J Med Chem 156:618-627
Tian, Ye; Liu, Zhaoqiang; Liu, Jinghan et al. (2018) Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. Eur J Med Chem 151:339-350
Huang, Li; Lai, Wei-Hong; Zhu, Lei et al. (2018) Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor. ACS Med Chem Lett 9:268-273
Wei, Lei; Wang, Hui-Ling; Huang, Li et al. (2017) Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. Bioorg Med Chem Lett 27:2788-2792
Zhao, Yu; Gu, Qiong; Morris-Natschke, Susan L et al. (2016) Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. J Med Chem 59:9262-9268
Jiang, Cheng; Luo, Pan; Zhao, Yu et al. (2016) Carolignans from the Aerial Parts of Euphorbia sikkimensis and Their Anti-HIV Activity. J Nat Prod 79:578-83
Li, Jizhen; Goto, Masuo; Yang, Xiaoming et al. (2016) Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity. Bioorg Med Chem Lett 26:68-71
Dang, Zhao; Zhu, Lei; Lai, Weihong et al. (2016) Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors. ACS Med Chem Lett 7:240-4
Liu, Na; Wei, Lei; Huang, Li et al. (2016) Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. J Med Chem 59:3689-704
Gao, Jiadi; Fang, Cheng; Xiao, Zhiyan et al. (2015) Discovery of novel 5-fluoro-N (2),N (4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9. Medchemcomm 6:444-454

Showing the most recent 10 out of 119 publications